Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer
- Authors
- Kim, Min-Jeong; Yeo, Seung-Gu; Kim, Eun Seok; Min, Chul Kee; Sean, Pyung
- Issue Date
- Mar-2013
- Publisher
- Spandidos Publications
- Keywords
- non-small cell lung cancer; medically inoperable; stage I; stereotactic body radiotherapy; intensity-modulated radiotherapy
- Citation
- Oncology Letters, v.5, no.3, pp 840 - 844
- Pages
- 5
- Journal Title
- Oncology Letters
- Volume
- 5
- Number
- 3
- Start Page
- 840
- End Page
- 844
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13862
- DOI
- 10.3892/ol.2012.1082
- ISSN
- 1792-1074
1792-1082
- Abstract
- This study aimed to investigate the clinical outcomes of intensity-modulated radiotherapy (IMRT)-based stereotactic body radiotherapy (SBRT) for patients with stage I non-small cell lung cancer (NSCLC). A prospective database of 16 consecutive patients receiving SBRT for pathologically-proven and peripherally-located stage I NSCLC was reviewed. Fifteen patients were medically inoperable and one patient refused to undergo surgery. The median age of the patients was 76 years (range, 69-86). Treatment planning used four-dimensional computed tomography and fixed-field IMRT (n=11) or volumetric-modulated arc therapy (V MAT; n=5). The SBRT scheme was 48 Gy in four fractions (n=9) or 55 Gy in five fractions (n=7), delivered on consecutive days. The overall response rate at 6 months was 78.6%, including a complete response in three (21.4%) patients and a partial response in eight (57.1%). Three patients (21.4%) demonstrated a stable disease status. The median follow-up time was 14 months (range, 6-20) for the surviving patients. One patient developed local failure at 11 months, while another suffered from regional failure in a subcarinal lymph node at 4 months. Two patients did not survive within the first 6 months; one patient died during salvage chemotherapy for mediastinal lymph node metastasis and the other succumbed to a cause unrelated to lung cancer. The Kaplan-Meier estimates of local failure-free, progression-free and overall survival rates at 18 months were 91.0, 85.2 and 87.5%, respectively. The toxicity was mild; no severe (grade >= 3) toxicity was identified. IMRT-based (including VMAT) delivery of SBRT for patients with stage I NSCLC demonstrated favorable responses and local control without severe toxicity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Radiation Oncology > 1. Journal Articles
- College of Medicine > Department of Radiation Oncology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.